chronic
obstruct
pulmonari
diseas
copd
exacerb
import
caus
consider
morbid
mortal
found
copd
copd
exacerb
increas
increas
sever
copd
patient
prone
frequent
exacerb
lead
hospit
admiss
readmiss
frequent
exacerb
may
consider
impact
qualiti
life
activ
daili
live
factor
increas
risk
copd
exacerb
associ
increas
airway
inflamm
caus
common
pollut
bacteri
andor
viral
infect
inflammatori
respons
caus
mucu
hypersecret
therebi
airway
obstruct
associ
exacerb
chronic
mucu
hypersecret
signific
risk
factor
frequent
sever
exacerb
patient
chronic
mucu
hypersecret
lower
rate
relaps
initi
treatment
acut
exacerb
benefit
antibiot
treatment
copd
exacerb
small
signific
mechan
action
clear
mucolyt
agent
reduc
number
day
disabl
subject
exacerb
reduc
mucou
cell
number
small
airway
could
use
way
reduc
chronic
mucu
hypersecret
studi
suggest
program
cell
death
crucial
resolut
metaplast
mucou
cell
understand
mechan
may
provid
novel
therapi
reduc
risk
copd
exacerb
chronic
obstruct
pulmonari
diseas
copd
chronic
condit
wherebi
airflow
limit
limit
caus
combin
underli
condit
notabl
chronic
bronchiti
emphysema
chronic
mucu
hypersecret
cmh
hallmark
chronic
bronchiti
cmh
common
caus
morbid
mortal
annual
preval
diagnos
chronic
bronchiti
million
unit
state
emphysema
alveolar
destruct
associ
loss
elast
recoil
lung
cigarett
smoke
major
etiolog
factor
predomin
condit
vari
among
individu
copd
caus
signific
morbid
mortal
econom
consequ
individu
copd
fourth
lead
caus
death
five
major
diagnos
copd
project
increas
annual
death
copd
develop
known
cure
despit
fact
copd
often
underdiagnos
million
peopl
unit
state
estim
copd
result
hospit
million
offic
visit
annual
copd
cost
billion
annual
medic
expenditur
occur
hospit
due
acut
exacerb
hospit
requir
poor
respons
manag
unrel
dyspnea
inabl
perform
activ
daili
live
copd
patient
hospit
admit
acut
exacerb
readmit
often
due
incomplet
recoveri
patient
recurr
within
month
readmit
within
year
percentag
predict
forc
expiratori
volum
second
fev
use
measur
sever
copd
associ
increas
occurr
exacerb
well
mortal
exampl
mannino
et
al
found
patient
fev
exacerb
annual
miravitl
et
al
report
less
sever
diseas
fev
averag
exacerb
annual
frequent
exacerb
past
best
predictor
exacerb
futur
spencer
jone
demonstr
recoveri
exacerb
take
week
pattern
rapid
improv
week
follow
prolong
recoveri
last
month
one
systemat
studi
symptom
exacerb
seemung
et
al
subject
prospect
evalu
year
number
exacerb
exacerb
identifi
symptom
diari
card
total
exacerb
actual
report
investig
mortal
increas
exacerb
death
rate
hospit
admiss
report
low
increas
within
year
highrisk
factor
mortal
requir
mechan
ventil
mortal
half
year
die
within
year
univers
definit
exacerb
like
singl
caus
identifi
often
two
patient
present
differ
occas
differ
patholog
find
well
differ
constel
symptom
frequent
accept
descript
exacerb
sudden
sustain
worsen
copd
beyond
normal
daytoday
variat
breath
event
natur
cours
diseas
character
chang
patient
baselin
dyspnea
cough
andor
sputum
dictat
chang
manag
major
exacerb
common
combin
follow
symptom
dyspnea
wheez
increas
cough
increas
amount
purul
sputum
accord
commonli
use
definit
therefor
exacerb
chang
consecut
day
three
major
sign
symptom
dyspnea
volum
sputum
sputum
purul
sever
determin
presenc
major
minor
symptom
minor
symptom
increas
cough
wheez
upper
respiratori
infect
uri
sore
throat
nasal
discharg
past
day
fever
increas
respiratori
rate
heart
rate
baselin
sever
exacerb
defin
increas
three
major
symptom
moder
exacerb
increas
two
major
symptom
mild
exacerb
one
major
one
minor
symptom
import
patient
report
symptom
diagnos
exacerb
underscor
fact
object
measur
peak
flow
read
spirometri
success
detect
exacerb
earli
earli
detect
key
earli
intervent
prevent
hospit
greater
understand
patholog
exacerb
certainli
lead
better
mean
treat
well
prevent
exacerb
unfortun
caus
exacerb
unclear
may
vari
within
patient
copd
patient
great
risk
repeat
exacerb
follow
initi
event
howev
half
patient
seek
care
symptom
occur
copd
patient
tend
wait
experienc
extrem
exacerb
either
occasion
frequent
report
doctor
increas
level
interleukin
il
found
sputum
patient
frequent
exacerb
baselin
stabl
compar
infrequ
exacerb
sputum
cell
count
inflammatori
cell
increas
baselin
patient
frequent
exacerb
increas
cytokin
product
may
origin
bronchial
epithelium
copd
exacerb
inflammatori
marker
includ
level
plasma
fibrinogen
serum
cytokin
rise
higher
viral
nonvir
exacerb
plasma
fibrinogen
level
vari
respons
viral
induc
exacerb
studi
subject
seemung
et
al
report
mean
plasma
fibrinogen
level
gl
viral
exacerb
versu
gl
nonvir
exacerb
exacerb
caus
bacteri
viral
infect
may
lead
pneumonia
condit
associ
exacerb
environment
pollut
cold
weather
seemung
et
al
report
nearli
event
n
z
copd
exacerb
respiratori
viru
infect
found
rhinovirus
common
virus
polymeras
chain
reaction
pcr
identifi
organ
nasal
aspir
subject
copd
exacerb
rhinoviru
predomin
organ
follow
respiratori
syncyti
viru
rsv
coronaviru
influenza
b
parainfluenza
chlamydia
pneumonia
virus
associ
chang
sputum
characterist
increas
volum
purul
relat
virus
detect
nasal
secret
howev
copd
exacerb
patient
viral
infect
higher
symptom
score
onset
exacerb
compar
nonvir
exacerb
time
requir
exacerb
resolv
symptomat
significantli
longer
viral
versu
nonvir
exacerb
vs
day
minimum
one
respiratori
viru
detect
exacerb
patient
patient
higher
frequenc
exacerb
p
howev
rsv
appear
relat
sever
exacerb
virus
identifi
pcr
serum
nasal
aspir
sampl
nasal
cultur
serolog
howev
neg
subject
report
least
one
exacerb
therefor
analysi
nasal
cultur
appear
good
method
detect
exacerb
airway
copd
patient
often
colon
bacteria
make
presenc
bacteria
insuffici
explain
worsen
airway
function
howev
increas
bacteri
number
chang
bacteri
locat
airway
acquisit
new
virul
proinflammatori
bacteri
speci
strain
could
caus
exacerb
patient
frequent
exacerb
also
increas
incid
colon
bacteria
hemophilu
influenza
moraxella
catarrhali
streptococcu
pneumonia
stabl
exacerb
increas
chanc
detect
bacteria
especi
exacerb
associ
presenc
purul
sputum
work
stockley
et
al
subject
purul
sputum
mucoid
sputum
exacerb
test
posit
bacteria
patient
h
influenza
colon
stabl
state
experienc
symptom
purul
exacerb
sputum
purul
exacerb
like
associ
high
bacteri
load
patient
symptom
cold
uri
like
exacerb
associ
viru
chronic
bronchiti
defin
presenc
chronic
recurr
increas
bronchial
secret
attribut
pulmonari
cardiac
caus
suffici
caus
daili
expector
minimum
month
year
least
success
year
populationbas
studi
report
associ
cmh
acceler
declin
fev
chronic
bronchiti
like
result
interact
intrins
extrins
factor
prevent
airway
diseas
crucial
limit
exogen
caus
airway
damag
also
identifi
treat
endogen
one
intrins
factor
may
base
genet
polymorph
make
smoker
suscept
develop
chronic
bronchiti
studi
anim
model
chronic
bronchiti
suggest
dysregul
express
may
lead
prolong
presenc
goblet
cell
metaplasia
gcm
subject
chronic
bronchiti
without
airway
obstruct
show
patholog
airway
copd
reason
natur
caus
exacerb
subject
copd
clear
howev
evid
environment
pollut
level
environment
air
well
allergen
infect
increas
incid
symptom
patient
chronic
bronchiti
emphysema
condit
known
induc
specif
type
inflamm
like
stimul
innat
acut
respons
immun
therefor
possibl
result
innat
immun
respons
environment
pollut
allergen
infect
sudden
secret
mucu
trigger
increas
number
mucusproduc
cell
caus
airway
obstruct
associ
exacerb
hospit
exacerb
occur
half
copd
patient
patient
averag
one
four
event
annual
given
lack
knowledg
patholog
exacerb
prevent
intervent
reduc
hospit
poorli
understood
frequent
exacerb
demonstr
neg
impact
qualiti
life
patient
copd
furthermor
frequent
caus
hospit
admiss
death
among
patient
chronic
lung
diseas
sinc
copd
exacerb
import
event
natur
histori
diseas
crucial
identifi
patient
risk
suffer
identif
risk
factor
exacerb
may
permit
implement
measur
aim
avoid
complic
patient
recognit
exacerb
symptom
earli
treatment
improv
recoveri
process
reduc
risk
hospit
earli
therapi
improv
outcom
exacerb
copd
reduc
cost
treatment
cmh
signific
predictor
hospit
due
copd
subject
copd
cmh
like
die
pulmonari
infect
subject
without
cmh
cmh
hallmark
chronic
bronchiti
particularli
associ
mortal
infecti
caus
observ
may
explain
affin
bacteria
mucu
impair
mucociliari
clearanc
chronic
bronchiti
provid
bacteria
inhal
aspir
bronchial
tree
opportun
colon
mucosa
impair
respiratori
function
may
import
govern
outcom
copd
exacerb
caus
bacteri
infect
chronic
bronchiti
exacerb
factor
bronchiti
turn
may
predispos
secondari
bacteri
infect
bacteri
product
certainli
potenti
independ
stimulu
inflamm
exampl
lipopolysaccharid
lp
potent
induc
varieti
inflammatori
mediat
includ
immunoregulatori
cytokin
resid
inflammatori
cell
lung
other
shown
lp
initi
induc
mucou
secret
follow
extens
mucou
cell
metaplasia
airway
epithelia
speed
recoveri
symptom
exacerb
import
patient
chronic
bronchial
diseas
patient
milder
symptom
may
return
work
usual
activ
earlier
patient
sever
symptom
may
avoid
respiratori
failur
recoveri
symptom
achiev
short
period
time
know
time
cours
symptom
risk
factor
late
recoveri
may
help
physician
schedul
followup
visit
interpret
outcom
therapi
failur
recov
associ
major
econom
implic
studi
aim
identifi
risk
factor
treatment
failur
reallif
condit
requir
studi
miravitl
et
al
follow
rate
recoveri
copd
exacerb
patient
primari
outcom
studi
time
resolut
symptom
fast
recoveri
defin
resolut
symptom
day
median
durat
symptom
whole
group
patient
recov
day
treatment
failur
defin
failur
return
baselin
day
persist
aggrav
symptom
requir
new
treatment
medic
first
day
patient
two
exacerb
hospit
exacerb
previou
year
like
slow
recoveri
interestingli
patient
chronic
bronchiti
reduc
risk
treatment
failur
compar
patient
emphysema
suggest
increas
expector
sputum
appear
help
speedi
recoveri
find
suggest
subject
unabl
expector
mucu
may
breath
difficulti
limit
activitydth
hallmark
acut
exacerbationsdbecaus
mucu
obstruct
airway
crosssect
observ
studi
copd
patient
sever
fev
impair
presenc
cmh
found
factor
independ
associ
increas
risk
suffer
two
acut
exacerb
copd
per
year
fev
impair
associ
increas
risk
hospit
admiss
cmh
significantli
associ
risk
admiss
presenc
signific
comorbid
diabet
mellitu
cardiac
insuffici
ischem
heart
diseas
miravitl
et
al
specul
age
cmh
facilit
factor
exacerb
sever
prognosi
exacerb
best
predict
presenc
absenc
signific
comorbid
condit
sever
studi
establish
comorbid
condit
risk
factor
refer
hospit
treat
acut
exacerb
anoth
prospect
studi
evalu
influenc
cmh
risk
frequent
exacerb
exacerb
frequenc
relat
bronchit
symptom
although
burrow
earl
mention
signific
associ
daili
sputum
product
observ
frequent
exacerb
even
though
patient
bronchit
symptom
usual
defin
present
persist
cough
sputum
product
possibl
patient
report
bronchit
symptom
defin
sever
symptom
report
sputum
product
respect
one
would
consid
cmh
daili
emiss
ml
expector
matter
burrow
earl
show
inform
regard
quantit
expector
studi
miravitl
et
al
suggest
cmh
render
patient
prone
suffer
recur
exacerb
determin
sever
exacerb
appear
factor
associ
hospit
admiss
therefor
clinic
assess
copd
patient
gener
practic
includ
import
easili
measur
variabl
summari
fev
impair
explain
part
risk
hospit
admiss
caus
frequent
exacerb
cmh
increas
age
significantli
associ
risk
frequent
exacerb
sever
exacerb
provok
hospit
admiss
associ
presenc
signific
comorbid
relaps
initi
treatment
acut
exacerb
may
lead
prolong
disabl
new
cours
antibiot
emerg
room
visit
even
hospit
admiss
therefor
crucial
identifi
patient
risk
relaps
identifi
risk
factor
ambulatori
treatment
failur
may
permit
implement
aggress
broadspectrum
treatment
closer
followup
therefor
risk
factor
associ
relaps
incorpor
manag
guidelin
aid
gener
practition
identifi
atrisk
patient
studi
miravitl
et
al
estim
probabl
relaps
ambulatori
treatment
exacerb
chronic
bronchiti
base
data
collect
clinic
record
obtain
visit
gener
practition
studi
diagnosi
acut
exacerb
base
presenc
combin
follow
symptom
increas
dyspnea
increas
product
purul
sputum
relaps
defin
unschedul
visit
gener
practition
month
persist
increas
symptom
led
chang
drug
prescript
emerg
visit
hospit
admiss
treatment
administ
acut
exacerb
includ
antibiot
case
oral
corticosteroid
case
case
mucolyt
agent
treatment
approxim
individu
exacerb
chronic
bronchiti
suffer
relaps
exacerb
follow
treatment
studi
show
ambulatori
treatment
acut
exacerb
chronic
bronchiti
patient
ischem
heart
diseas
visit
gener
practition
three
time
last
year
respiratori
problem
relaps
probabl
statist
significantli
higher
mean
probabl
gener
cohort
similarli
ball
et
al
found
factor
signific
predict
failur
recov
acut
infect
exacerb
chronic
bronchiti
histor
neither
clinic
featur
present
antibiot
treatment
affect
recoveri
best
combin
predict
return
chest
problem
histori
cardiopulmonari
diseas
four
acut
exacerb
within
past
month
consid
high
preval
chronic
bronchiti
gener
popul
high
number
medic
consult
gener
popul
crucial
identifi
patient
risk
failur
treatment
exacerb
risk
repeat
consult
respiratori
problem
patient
exhibit
factor
receiv
energet
treatment
broadspectrum
antibiot
short
cours
oral
corticosteroid
close
follow
attempt
avoid
relaps
signific
number
case
may
lead
hospit
admiss
even
caus
death
gener
antibiot
commonli
prescrib
exacerb
evid
appreci
alter
outcom
accept
anthonisen
et
al
show
signific
benefit
antibiot
compar
placebo
patient
judg
moder
sever
exacerb
basi
increas
dyspnea
sputum
product
purul
sputum
stockley
et
al
specifi
patient
like
benefit
antibiot
treatment
presenc
green
purul
sputum
specif
high
bacteri
load
subset
patient
whose
episod
identifi
present
like
benefit
antibiot
treatment
studi
show
patient
produc
white
mucoid
sputum
acut
exacerb
recov
without
antibiot
treatment
recent
metaanalysi
trial
includ
placebocontrol
studi
involv
small
number
patient
show
overal
small
signific
benefit
antibiot
treatment
acut
exacerb
copd
bacteri
speci
infect
bronchial
tree
also
form
part
commens
nasal
pharynx
eg
h
influenza
opportunist
pathogen
eg
p
aeruginosa
mucos
infect
usual
superfici
major
bacteria
resid
lumen
associ
secret
wherea
proport
adher
epitheli
surfac
particularli
area
epitheli
damag
infiltr
mucosa
repeat
injuri
highdos
inhal
atmospher
pollut
tobacco
smoke
ozon
lead
chronic
inflammatori
cell
infiltr
mucosa
lymphocyt
monocyt
macrophag
neutrophil
lesser
extent
eosinophil
attract
airway
lumen
product
may
impair
host
defens
neutrophil
releas
proteas
neutrophil
elastas
reactiv
oxygen
speci
damag
epitheli
cell
stimul
mucu
product
epitheli
cell
also
activ
particip
inflammatori
reaction
releas
proinflammatori
mediat
includ
cytokin
chemokin
nitric
oxid
inflammatori
respons
caus
mucu
hypersecret
chang
morpholog
airway
involv
loss
ciliat
cell
increas
number
goblet
cell
mucos
gland
hypertrophi
bronchit
airway
therefor
vulner
infect
also
wellprim
immun
system
present
readi
mount
inflammatori
respons
insult
bacteria
avoid
clearanc
produc
factor
impair
mucociliari
clearanc
paralyz
ciliari
beat
stimul
mucu
product
produc
enzym
break
local
immunoglobulin
display
antigen
heterogen
avoid
immun
surveil
grow
biofilm
adher
epithelium
surviv
within
epitheli
cell
form
microcoloni
surround
polysaccharid
gel
report
pool
black
summar
therapeut
potenti
mucolyt
agent
prevent
exacerb
chronic
bronchiti
copd
studi
patient
defin
chronic
bronchiti
often
defin
presenc
cough
product
sputum
day
minimum
day
per
year
least
consecut
year
remain
two
studi
patient
copd
defin
diseas
character
airflow
limit
fulli
revers
like
patient
chronic
bronchiti
also
copd
patient
smoker
lung
function
measur
evid
airway
obstruct
studi
mucolyt
agent
use
nacetylcystein
nac
mucolyt
agent
use
ambroxol
carbocystein
sorbrerol
letostein
cithiolon
iodin
glycerol
nisobutyrylcystein
myrtol
ten
studi
conduct
itali
three
scandinavia
germani
four
unit
kingdom
two
sever
european
countri
one
unit
state
studi
similar
score
standard
review
found
annual
exacerb
rate
per
year
control
group
reduc
treatment
patient
mucolyt
agent
similar
studi
show
reduct
anoth
studi
found
patient
receiv
mucolyt
agent
twice
like
exacerb
studi
period
receiv
placebo
treatment
mucolyt
agent
result
fewer
day
disabl
per
patient
per
month
find
base
six
studi
support
result
four
studi
mean
day
disabl
standard
deviat
valu
report
two
systemat
review
effect
nac
patient
chronic
bronchiti
shown
patient
treat
nac
like
remain
exacerb
free
patient
like
report
improv
symptom
nac
placebo
mucolyt
agent
work
varieti
way
potenti
mechan
action
includ
thin
produc
sputum
result
promot
expector
antioxid
antibiot
activ
also
postul
mucolyt
agent
may
work
via
antioxid
mechan
gener
accept
play
role
pathogenesi
copd
acut
exacerb
copd
oxidantantioxid
imbal
profound
studi
need
determin
whether
mucolyt
agent
acut
reduc
morbid
event
third
possibl
mucolyt
agent
may
work
antibacteri
immunostimulatori
mechan
pretreat
nac
result
significantli
fewer
patient
posit
cultur
intrabronchi
sampl
addit
nac
shown
reduc
adhes
pneumonia
oropharyng
epitheli
cell
mucolyt
therapi
appear
safe
well
toler
suggest
studi
increas
incid
advers
effect
rel
placebo
nac
mucolyt
agent
extens
studi
howev
mucolyt
agent
overal
similar
effect
exacerb
rate
patient
frequent
prolong
exacerb
repeatedli
admit
hospit
would
appear
gain
broncu
studi
compar
effect
nac
placebo
copd
patient
number
exacerb
per
year
found
nac
fail
effect
prevent
exacerb
patient
appear
reduc
risk
exacerb
patient
take
inhal
steroid
differ
find
studi
previou
studi
may
fact
previou
studi
assess
chronic
bronchiti
rather
copd
furthermor
author
broncu
studi
acknowledg
greater
dose
nac
increas
dose
mg
daili
could
result
improv
effect
anoth
studi
show
mg
daili
improv
lung
function
idiopath
pulmonari
fibrosi
well
toler
main
difficulti
interpret
result
studi
treat
chronic
bronchiti
exacerb
includ
heterogen
condit
caus
exacerb
includ
acut
viral
bronchiti
environment
pollut
allerg
respons
well
bacteri
infect
furthermor
heterogen
within
definit
sever
exacerb
exist
sever
classif
base
symptomatolog
chronic
bronchiti
exacerb
thu
far
larg
empir
valid
clinic
trial
classif
sever
base
clinic
paramet
easili
evalu
would
allow
detect
differ
efficaci
new
therapi
compar
placebo
improv
convent
manag
exacerb
site
mucu
hypersecret
larg
airway
histolog
studi
show
enlarg
tracheobronchi
submucos
gland
hyperplasia
presenc
increas
number
goblet
cell
distinguish
patient
cmh
airway
obstruct
patient
cmh
without
obstruct
hyperplasia
mucou
goblet
cell
mucu
plug
note
patient
chronic
bronchiti
without
emphysema
therefor
understand
caus
increas
number
mucou
cell
crucial
reduc
sever
copd
exacerb
detail
morphometr
analysi
amount
sustain
store
secretori
product
tracheobronchi
airway
rhesu
monkey
reveal
least
twice
much
mucu
surfac
epithelium
submucos
gland
lower
airway
rhesu
monkey
major
anim
speci
gland
absent
surfac
epitheli
mucou
cell
sole
sourc
mucu
surfac
epitheli
mucou
cell
repres
great
potenti
secret
mucosubst
import
investig
number
regul
airway
epithelia
normal
tracheobronchi
epithelium
contain
ciliat
basal
secretori
cell
maintain
fix
ratio
homeostat
mechan
proport
cell
type
perturb
follow
variou
inflammatori
respons
mechan
injuri
epithelium
due
prolifer
variou
studi
shown
noncili
columnar
cell
main
cell
type
recruit
cell
cycl
larger
number
gcm
follow
acut
injuri
inflammatori
respons
result
differenti
preexist
epitheli
cell
mucou
cell
differenti
prolifer
cell
mucou
cell
follow
cessat
allergen
exposur
airway
epithelia
return
origin
proport
cell
type
variou
mechan
may
respons
reduct
gcm
includ
fact
inflammatori
mediat
respons
mucin
synthesi
longer
present
howev
full
recoveri
epithelium
necessit
reduct
epitheli
cell
number
origin
state
studi
suggest
abrog
mechan
may
least
part
respons
persist
chang
airway
epithelia
observ
airway
subject
cmh
small
airway
subject
copd
detach
alveolar
connect
result
loss
support
closur
small
airway
expir
addit
airway
narrow
result
inflamm
scar
importantli
due
block
lumen
mucou
secret
exacerb
occur
number
mucussecret
cell
small
airway
present
secret
content
result
increas
inflamm
caus
exposur
new
bacteri
viral
infect
environment
pollut
ozon
particl
allergen
wide
believ
factor
caus
copd
exacerb
believ
larg
increas
inflamm
increas
inflamm
may
primarili
caus
increas
secret
mucu
metaplast
goblet
cell
immedi
obstruct
small
airway
reduc
complet
block
airflow
increas
number
mucou
cell
present
epithelium
capabl
regul
number
presenc
mucou
cell
detriment
symptomfre
condit
increas
inflamm
caus
exacerb
reduc
pulmonari
function
increas
cough
sputum
secret
due
sudden
secret
larg
amount
mucu
lumen
blockag
airway
enhanc
sticki
natur
mucu
trap
inflammatori
cell
releas
dna
increas
mucu
viscos
develop
anim
model
epitheli
cell
number
gcm
increas
airway
epithelia
studi
role
sustain
gcm
instil
bacteri
lp
rat
caus
number
epitheli
cell
increas
approxim
addit
prolifer
cell
exist
serou
cell
differenti
mucou
cell
follow
recoveri
day
number
epitheli
cell
reduc
found
noninstil
control
rat
attempt
understand
mechan
reduc
number
metaplast
mucou
cell
inflammatori
respons
subsid
analyz
express
regul
program
cell
death
famili
cytoplasm
protein
regist
divers
form
intracellular
damag
gaug
whether
cell
provid
posit
neg
death
stimulu
determin
progress
inhibit
suicid
program
inhibitor
apoptosi
belong
member
famili
protein
antiand
proapoptot
properti
overexpress
prevent
induc
apoptosi
respect
proand
antiapoptot
famili
member
heterodimer
rel
concentr
determin
whether
cell
live
die
protein
function
regul
releas
cytochrom
c
mitochondria
initi
cascad
event
lead
activ
caspas
dnase
respons
appear
apoptot
morpholog
includ
dna
fragment
chromatin
condens
membran
bleb
cell
shrinkag
disassembl
cell
enhanc
cell
surviv
inhibit
apoptosi
induc
wide
varieti
circumst
extend
cell
surviv
prevent
cell
death
differ
cell
type
respons
differ
stimuli
suggest
act
central
control
point
pathway
apoptot
cell
death
express
regul
cytokin
deathsurviv
signal
transcript
posttranscript
phosphoryl
determin
mucou
cell
deriv
prolifer
cell
also
preexist
cell
result
show
involv
cell
cycl
progress
cell
fig
follow
observ
suggest
express
sustain
gcm
demonstr
brown
norway
fischer
rat
follow
singl
intratrach
instil
lp
inhibitor
apoptosi
must
downregul
mucou
cell
number
reduc
mrna
downregul
antisens
oligodeoxynucleotid
gcm
subsequ
reduc
organ
cultur
vivo
rat
rat
endogen
mucou
cell
found
epithelia
line
proxim
mid
septa
cell
approxim
posit
percentag
chang
significantli
follow
exposur
ozon
howev
exposur
ozon
induc
gcm
transit
epithelia
line
later
wall
nasal
maxillari
turbin
percentag
posit
metaplast
mucou
cell
exce
result
show
low
endogen
mucou
cell
express
high
percentag
metaplast
mucou
cell
nasal
epithelia
observ
suggest
could
use
target
elimin
metaplast
mucou
cell
without
affect
endogen
mucou
cell
anoth
group
research
use
microarray
approach
identifi
one
gene
express
follow
smokeinduc
injuri
human
bronchial
epitheli
cell
line
confirm
observ
northern
blot
assay
collect
studi
show
express
mucou
cell
found
anim
human
fig
injuri
airway
epithelium
lp
caus
airway
epitheli
hyperplasia
mucou
cell
metaplasia
prolifer
denot
black
nuclei
preexist
cell
produc
store
mucu
denot
vesicl
columnar
cell
cell
shown
mucou
cell
black
stain
around
vesicl
follow
day
epitheli
cell
number
reduc
essenti
number
observ
injuri
epithelium
gcm
may
persist
subject
chronic
bronchiti
repeat
injuri
epithelium
due
repeat
exposur
allergen
cigarett
smoke
environment
andor
occup
pollut
chronic
infect
interact
variou
factor
also
possibl
defici
abil
epithelium
revers
chang
woundheal
process
inflammatori
respons
may
subsid
genet
makeup
epithelium
lead
inabl
epithelium
heal
caus
gcm
persist
follow
observ
support
hypothesi
transgen
mice
show
resolut
lpsinduc
gcm
day
lp
exposur
wildtyp
litterm
hors
recurr
airway
obstruct
also
call
copd
increas
airway
secret
mucu
obstruct
airflow
significantli
higher
percentag
mucou
cell
compar
control
hors
person
observ
increas
gcm
copd
symptomfre
period
detriment
sudden
mucu
secret
increas
number
mucusproduc
cell
trigger
infect
environment
pollut
allergen
may
block
nonelast
airway
emphysema
patient
caus
exacerb
process
lead
dyspnea
increas
sputum
product
hallmark
acut
exacerb
identif
molecular
mechan
relat
develop
persist
copd
cmh
may
help
develop
novel
strategi
reduc
debilit
symptom
associ
copd
exacerb
precis
caus
copd
exacerb
known
evid
suggest
infecti
process
take
place
evid
seen
cellular
level
biomark
infecti
agent
cytolog
clinic
observ
chang
sputum
cmh
risk
factor
copd
exacerb
treatment
mucolyt
agent
shown
reduc
day
disabl
subject
copd
exacerb
therefor
effect
reduc
number
metaplast
goblet
cell
small
airway
may
use
reduc
risk
exacerb
rate
relaps
treatment
copd
exacerb
